Grifols Nordic AB

Image of the headquarters of Grifols in Sweden

Grifols was founded in 1940 and is today a global healthcare company represented in almost 100 countries. Our mission is to improve health and wellbeing of people by providing safe and high quality products and services.

Grifols Nordic AB was established in 2010 as the platform for sales and marketing of Grifols products in the Nordic countries (Sweden, Norway, Denmark, Iceland and Finland). The two business areas are Diagnostic and Bioscience. Our mission and goal are to make Grifols Nordic known as an ethical, serious and trustworthy supplier in the Nordic region.

Diagnostic

Products for laboratory analysis, hospital blood banks and transfusion centers.

The products are marketed and sold by Electra-Box Diagnostica in the Nordic countries.

For information please contact

Electra-Box Diagnostica AB
Tel: +46(0)8 448 73 70
Contact person: Christer Lidén
Mobile: +46 708 72 2309
E-mail: christer.liden@electrabox.com

Bioscience

Plasma products are the original and core products for Grifols. With local variations, the following products are available in the Nordic countries;

Do not hesitate to contact us for information about our products and services as well as the availability of our products in your country.

  • Intravenous immunoglobulins, IVIg:
    • Gamunex® 100 mg/ml;
    • Flebogamma®DIF 50 mg/ml and 100 mg/ml
  • Alpha1-proteinase inhibitor:
    • Prolastina®

 

GRIFOLS NORDIC AB

Sveavägen 166
113 46 Stockholm
SWEDEN

Contact information:
Tel: +46 (0) 8 441 89 50
infonordic@grifols.com

General Manager Anders Åsell:

anders.asell@grifols.com
Business Manager Anki Book:

anki.book@grifols.com
Project Manager Pål Faxén:

pal.faxen@grifols.com

News


Grifols improves safety of transfusions with its ID CORE XT diagnostic kit The molecular diagnostic kit available in the United States since last year has obtained CE marking. The diagnostic kit offers greater donor–patient compatibility by testing 37 antigens of 10 blood groups in less than 4 hours on the basis of a DNA sample. According to WHO data, 5% of the world's population carry genes for hereditary blood disorders, and each year over 300,000 children are born suffering from these conditions.
+ info

Grifols launches a continuing education program for transfusion medicine professionals in the United States The program is designed to update knowledge and share advances in the field of transfusion safety.
+ info

Grifols opens state-of-the-art facility in Clayton, NC to help advance treatment of rare and life-threatening diseases Grifols' North Fractionation Facility will be the world's largest and one of the most technologically advanced plasma fractionation facilities, increasing production capacity in Clayton from 3.2 million liters of plasma annually to 6 million liters in 2015
+ info

Grifols announces availability in Europe of AlphaKit®QuickScreen, a novel point-of-care screening device to aid in the detection of Alpha-1-Antitrypsin Deficiency (AATD) AlphaKit® QuickScreen is a novel point-of-care immuno-chromatographic, in vitro diagnostic screening test for the Z-form of Alpha-1-Antitrypsin (Z-AAT)
+ info

Grifols' fractionation facility in Clayton receives the ISPE 2014 Facility of the Year award The International Society for Pharmaceutical Engineering awarded the prize to the North Fractionation Facility in the category for Project Execution
+ info

Grifols Los Angeles site is awarded "Highly Protected Risk (HPR)" status The HPR award recognizes the highest level asite can achieve in terms of prevention and protection
+ info

Grifols Celebrates World Hemophilia Day with Donation of Coagulation Medicines to the World Federation of Hemophilia Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries
+ info

Grifols opens new plasma fractionation plant in Spain The company has invested over 20 million euros, doubling its plasma fractionation capacity in Spain
+ info

Japanese Red Cross selects Grifols as partner for nucleic acid screening of nation's blood supply Japanese Red Cross will use the Procleix® Panther® platform to screen approximately 5.3 million blood donations each year for HIV and Hepatitis viruses
+ info

Grifols' sales rose by 4.6% to Euros 2,741.7 million In 2013 Grifols maintained its position as the third largest producer of plasma derivatives
+ info

Grifols opens new head office of Araclon Biotech in Zaragoza (Spain) Araclon is an R&D company specializing in immunotherapy and diagnosis of Alzheimer's and other degenerative diseases
+ info

Vall d'Hebron Research Institute (VHRI) collaborates with Grifols to create a center of excellence for research into alpha 1-antitrypsin deficiency The aim of the project is to improve our understanding of patients with alpha-1-antitrypsin deficiency
+ info

The Fundació ACE, with the support of Grifols, opens a new center for the treatment and research of Alzheimer's disease The "Barcelona Alzheimer Treatment & Research Center" is operated by Fundació ACE as an independent center with the aim of facilitating the diagnosis and treatment of Alzheimer's and other neurodegenerative diseases, and promoting biomedical research into these conditions
+ info


Grifols contributes to transfusion medicine education with the third edition of the Transfusion Science Educational Course Grifols delivers a number of courses each year to help train and advance the careers of transfusion medicine professionals who in turn ensure the quality and safety of the blood transfusions
+ info


Grifols Announces Winners of the 10th Annual eALTA Research Fellowship at 2013 ERS Congress Awards fund early career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
+ info

Grifols takes part in the exhibition "Molecules of Life: 50 years of Biochemistry and Molecular Biology in Spain" Grifols sponsors the module dedicated to "Plasma Proteins" which consists of an augmented reality system
+ info

Grifols Implements Its First Automated Inventory Management Carousel System for Investigational Pharmacies at Emory University The first automated inventory management carousel has been implemented at Emory University Investigational Drug Service
+ info

Grifols increases its collaboration with the Chronic Liver Failure European Consortium The company will contribute three million euros over the next four years, in addition to the two million committed since 2009
+ info

Award Winners at the Sixth Edition of the Martín Villar Research Awards Grifols is a company which is committed to encouraging scientific investigation; one of the ways does this is through the Martín Villar Awards for research into haemostasis.
+ info

Grifols Announces Transfer of Management of Melville, New York Plasma Fractionation Facility to Kedrion Today Grifols, S.A. (Grifols) announced that effective July 1, 2013, it will transfer management of the Melville
+ info


Grifols officially inaugurates new immunoglobulin plant in the United States IVIGs are the most important and most widely consumed plasma derived protein therapies
+ info

Cadence Pharmaceuticals entrust Grifols the manufacturing of OFIRMEV® (paracetamol) injection in flexible IV bags Manufacturing and supply agreement between Cadence Pharmaceuticals and Grifols
+ info


Grifols' Alzheimer research strategy addresses the degenerative disease from a global perspective The company presented its research projects to coincide with World Alzheimer's Day, held on September 21
+ info

Grifols agrees to purchase three plasma donation centers in the United States from Canada's Cangene Once the transaction is concluded, Grifols has 150 plasmapheresis centers
+ info

Grifols Awards Winners of the 9th Annual eALTA Research Fellowship at 2012 ERS Meeting Awards fund early-career investigators' research to advance understanding and treatment of alpha1-antitrypsin deficiency.
+ info

Araclon Biotech has identified a new blood protein with diagnostic value for Alzheimer's disease The Spanish biotech firm, in which Grifols has a majority shareholding, has presented the first results at the Alzheimer's Association International Conference in Vancouver (Canada)
+ info

Grifols acquires 40% of the capital of biotechnology firm VCN Bioscience The group's investment will ensure the viability of research projects in the field of oncology
+ info

Award Winners at the Fifth Edition of the Martín Villar Research Awards Grifols is a company which is committed to encouraging scientific investigation; one of the ways does this is through the Martín Villar Awards for research into haemostasis
+ info

Grifols launches AMBAR study, based on the combined use of plasma derivatives and plasmapheresis to treat Alzheimer's disease The new AMBAR study combines therapeutic plasmapheresis with alternating infusion of albumin and intravenous immunoglobulin (IVIG) to treat Alzheimer's
+ info


Grifols continues to contribute to transfusion medicine training with its second European edition of the Transfusion Science Education Course Each year, Grifols holds a number of courses intended to provide an opportunity for transfusion medicine professionals to learn and progress. Through training we can ensure the quality and safety of the transfusions that millions of people throughout the world receive each year.
+ info

Grifols extends its commitment to scientific dissemination with a new publication, Perspectives in Transfusion Medicine The twice-yearly publication is a means of distributing scientific content developed by leading researchers in the field of transfusion medicine.
+ info

Grifols Opens New, State of the Art Plasma Testing Laboratory in San Marcos The 72,000-square-foot-facility will create new jobs as well as provide job opportunities for existing Grifols employees through consolidation of the company's plasma testing operations at the new San Marcos facility and an existing facility in Austin, Texas.
+ info

Pau Gasol introduces new technology, donated by Grifols, to pharmacy at Children's Hospital Los Angeles New equipment designed to enhance safety and efficiency by automating quality control oversight during compounding of medications
+ info

Grifols' sales increase by 7,7% in constant currency terms in 2011 to 2,300 millon euros Grifols leads global sales of IVIG and A1P1 (used to treat pulmonary emphysema) after Talecris acquisition
+ info

Award Winners at the Fourth Edition of the Martín Villar Research Awards Grifols is a company which is committed to encouraging scientific investigation; one of the ways is does this is through the Martín Villar Awards for research into hemostasis.
+ info


Grifols´ sales grow 10.0% to 261.4 million Euros in the first quarter of 2011 Strong growth in the United States where sales increased by 24.8% during the quarter. Higher sales volumes of plasma derivatives such as IVIG and factor VIII confirm the upward trend in the sector.
+ info

Grifols establishes Expert Advisory Council in Transfusion Medicine The role of the Expert Advisory Council is to provide insight, advice and guidance to Grifols´own transfusion medicine research and development activities.
+ info

Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US Agreement will facilitate access to state-of-the-art immunohematology products to blood banks and hospitals transfusion centers in the US.
+ info

Grifols starts construction of a new plasma fractionation plant in Parets del Vallès The new facilities will deliver up to an additional maximum of two million liters of plasma fractionation capacity in Spain raising total capacity from the current figure of 2.1 million liters to 4.1 million liters.
+ info

Grifols obtains EMA license to market its Flebogamma® DIF at 10% concentration · The approval means that Grifols now offers two concentrations of intravenous immunoglobulin (IVIG): 5% and 10%, allowing it to better respond to the needs of European health professionals and patients · Grifols´patented production process, developed at its Barcelona plant, ensures the highest standards of product quality and safety
+ info

Grifols updates the PediGri® website As of today, PediGri® has a new website at the following address: www.pedigri.grifols.com
+ info

Grifols´ turnover increased by 7.1% in the first nine months of 2010 to 738.8 MM Grifols reaches its highest quarterly turnover, exceeding 251 million Euros between July and September 2010. In the third quarter, the Bioscience division grew by 14.6% mainly driven by the U.S. market. The higher sale volumes of plasma derivatives such as albumin and IVIG, with double-digit increases, confirm the upward trend of the sector. Recurrent EBITDA of the business grew by 2.5% up to 212.1 million Euros. Net profit, at 97.0 million Euros, falls by 17.1% due to costs associated with the corporate transaction and higher financial expenses.
+ info

Grifols continues investing to boost its Diagnostics division A new plant will produce the MDmulticard® for the rapid determination of blood groups, expanding Grifols´offer in Transfusion Diagnostics. Investment made in production facilities in Australia and Switzerland amounts to 9 million euros.
+ info

Progenika Biopharma grants Grifols Worldwide distribution of its Bloodchip® genotyping test for blood donors The Spanish biotechnology company Progenika Biopharma is a pioneer in the development of molecular biology tests for blood transfusion compatibility. The BLOODCHIP® global distribution agreement strengthens Grifols´the Diagnostic Division, and is expected to generate revenues of between 50-100 million over the next 5 years. Bloodchip® assures the global reach of the test.
+ info

Grifols to acquire Talecris Biotherapeutics creating a world leading provider of life-saving plasma protein therapies The combination of Grifols and Talecris will create a diversified, global provider of life-saving and life enhancing plasma protein therapeutics built on the strong global presence of Grifols and the established position of Talecris in the United States and Canada. The merger accelerates key strategic initiatives for both Talecris and Grifols as it creates a more efficient platform for manufacturing, innovation and global sales and marketing. Combining the expertise of both companies will build upon their individual legacies of patient commitment, growth and innovation while increasing the availability of high quality plasma protein therapies for patients worldwide.
+ info

Grifols agrees to acquire intellectual property for treatment of post-polio syndrome from pharmalink AB Grifols also acquires US, European and Japanese patents for a specific PPS treatment method utilizing human immunoglobulin and unrestricted use of existing Pharmalink clinical trial data supporting the treatment method.
+ info

Moving forward in safety: Grifols introduces a holographic seal on its plasma derivative packaging. The holographic seal on its plasma derivative packaging is a an additional measure adopted by Grifols in its commitment to giving its products the highest levels of safety
+ info

Fundación Probitas provides aid for Haitian population Fundación Probitas, which was created in 2008 under the auspices of Grifols, has now started to operate, and as its first action has approved emergency aid for the Haitian population.
+ info

Grifols obtains FDA approval for new sterile albumin filling plant in Los Angeles Grifols has received approval from the FDA for its new sterile albumin filling plant in Los Angeles. This approval is the culmination of a three-year project to transform the entire process of obtaining, purifying and filling albumin vials at Grifols Biologicals Inc. (Los Angeles).
+ info

Grifols publishes interim results of its clinical trial on Alzheimer's disease The preliminary results of the trial suggest that patients who received treatment showed a trend towards stabilization of the disease The line of investigation was based on the systematic practice of therapeutic plasmapheresis with Human Albumin Grifols in patients with this disease
+ info

Work recognised in the 2nd edition of the Martín Villar Haemostasis Awards Researcher Giancarlo Castaman wins first prize for his study into the response of Von Willebrand patients to treatment with desmopressin
+ info

The annual Martin Villar Haemostasis Awards is open to applications El plazo de presentación de candidaturas a los premios Martín Villar se ha abierto oficialmente con dotaciones económicas que suman un total de 40.000 euros para los trabajos ganadores.
+ info

Grifols promotes European research into liver cirrhosis The European Consortium for the Study of Chronic Liver Failure, created today, brings together 70 centres from across Europe, and will be coordinated from Barcelona´s Hospital Clínic by Professor Vicente Arroyo.
+ info

New method makes it possible to transport medicine cells to areas affected by inflammatory processes This discovery, the product of collaboration between research centres and the Grifols group of companies, is a step towards what has been described as the medicine of the future: personalized therapy.
+ info

Grifols Academy of Plasmapheresis opens in US Based in Arizona in the United States, the initiative reflects a firm commitment to employee training and knowledge sharing in line with the degree of specialisation required in the plasma derivative industry
+ info

Grifols gets a minority stake in Cardio3 BioSciences Founded by a group of scientists from the Cardiovascular Center in Aalst, Belgium on a technology developed by researchers at Mayo Clinic, Cardio3 BioSciences specialises in stem-cell based biotherapeutic R&D for the treatment of cardiovascular diseases.
+ info

The Martin Villar Haemostasis Awards ceremony held in Barcelona Established by Grifols in 2007, these awards pay tribute to the world-renowned hematologist Martín Villar and promote research in hemostasis by recognizing the most outstanding basic or clinical research projects on blood coagulation disorders.
+ info

Grifols presents BlisPack®, an automated blister identification and opening tool for medications in the hospital BlisPack® was launched at the 53rd National Congress of the Hospital Pharmacy Spanish Society in Valencia, October 22 to 24
+ info

Grifols acquires office complex in Sant Cugat The new complex will allow the Grifols group to centralize its shared corporate areas, while also providing space for future growth. These areas are currently based in rented office space, primarily in Barcelona, and without any scope for physical expansion.
+ info

Final stage of implementation of PediGri® On Line extends transparency of information to all Grifols plasma derivatives Grifols has extended PediGri® On Line to all of its plasma derivatives including Albutein®, Alphanate®, AlphaNine® and Profilnine® SD. Also as part of the final stage, the company has officially launched PediGri® On Line in the US market.
+ info

Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement Cardinal Health and Grifols concluded an exclusive 6 year distribution agreement
+ info

Grifols signs agreement with Stough Development Corp. to open 10 new plasma collection centers in the United States As a result, the Spanish group expects to obtain an additional 400,000 of its main raw material, without allocating any internal resources to this
+ info

get to know us better

get to know us better